Last Updated: 21 April 2026
Oxford Biomedica plc (LSE: OXB) is a leading viral vector contract development and manufacturing organisation (CDMO) specialising in lentiviral and adeno-associated virus (AAV) vectors for cell and gene therapies. The company has transformed from a clinical-stage biotech into a pure-play CDMO and achieved its first full-year operating EBITDA profit in FY2025 (£8.1m) on revenue of £170.9m (+33% YoY). With a revenue backlog of £204m, contracted client orders of £224m and FY2026 guidance of £220–240m, Oxford Biomedica is scaling into a market projected to grow from ~$4bn in 2025 to $10bn by 2031. In April 2026, OXB launched its Fast-Track viral vector development service, cutting industry-standard lentiviral development timelines from 12–18 months to as little as nine months. This report covers every material angle. No analyst opinions or price targets. For live pricing see our live charts, upcoming releases on the economic calendar, and discussion on the ChartsView forum.
<\!-- TradingView Advanced Chart -->1. Company Snapshot
| Field | Value |
|---|---|
| Company | Oxford Biomedica plc |
| Ticker / Exchange | OXB / LSE (AIM graduated to Main Market) |
| Sector (ChartsView) | Healthcare & Pharma — Gene & Cell Therapy CDMO |
| GICS classification | Health Care / Life Sciences Tools & Services |
| Headquarters | Windrush Court, Transport Way, Oxford, OX4 6LT, UK |
| Chief Executive Officer | Dr Frank Mathias (since March 2023) |
| CFO | Stuart Paynter |
| Chairman | Dr Frédéric Roch Doliveux (since 2020) |
| Founded | 1995 (Oxford University spin-out by Prof. Alan Kingsman and Dr Susan Kingsman) |
| Employees | ~1,000 worldwide |
| Fiscal year end | 31 December |
| FY2025 revenue | £170.9m (+33% YoY at constant currency) |
| FY2025 operating EBITDA | £8.1m (first full-year profit since CDMO refocus) |
| FY2025 net loss | ~£37m (IFRS, including non-cash items) |
| Revenue backlog (31 Dec 2025) | ~£204m (+36% YoY) |
| Contracted client orders | £224m (+20% YoY) |
| FY2026 revenue guidance | £220–240m (constant currency) |
| FY2026 EBITDA margin guidance | ~10% full-year (H1 expected EBITDA-negative due to maintenance/integration) |
| Medium-term targets | 25–30% revenue growth p.a. 2027–28; ≥20% EBITDA margin by 2027 |
| Late-stage + commercial programs | 8 (as of March 2026, up from 6 in FY2025) |
| Shares outstanding | ~120.9m |
| Market cap (April 2026) | ~£750m |
| Website | oxb.com |
2. Bull Case vs Bear Case
Distilled from the full report below — factual only, no ratings.
Bull Case
- Structural growth market: The viral vector CDMO market is projected to grow from ~$4bn (2025) to ~$10bn by 2031 as gene and cell therapies move from clinical to commercial. Approximately 75% of production is outsourced to CDMOs like OXB.
- Revenue inflection confirmed: Revenue has nearly doubled from ~£90m (2023) to £170.9m (2025), growing at ~30% CAGR and significantly outpacing the 12% market CAGR.
- First EBITDA profit: FY2025 operating EBITDA of £8.1m marks the inflection to profitability. FY2026 targets ~10% margin with a path to ≥20% by 2027.
- BMS commercial supply agreement: New multi-year commercial supply agreement with Bristol Myers Squibb for lentiviral vector manufacture for CAR-T programmes, announced February 2026. Commercial manufacturing to start in 2026.
- Pipeline deepening: Late-stage and commercial programs rose from 5 (FY2024) to 8 (March 2026). At least one is expected to reach commercial launch in 2026, with additional programs following. Each commercial launch represents recurring, high-margin manufacturing revenue.
- AAV expansion: AAV opportunities have surpassed lentiviral for the first time in OXB’s pipeline (43% AAV vs 40% lentiviral), broadening the addressable market beyond CAR-T.
- US manufacturing footprint: Acquisition of FDA-approved Durham (NC) facility gives OXB end-to-end US manufacturing, critical for US-domiciled pharma clients and regulatory proximity.
- Fast-Track platform: April 2026 launch cuts lentiviral development timelines by up to 50% (from 12–18 months to ~9 months), a significant competitive differentiator for clients racing to IND filings.
- Revenue visibility: ~60% of FY2026 guidance covered by contracted orders; >80% including risk-adjusted pipeline.
Bear Case
- Still IFRS loss-making: Despite EBITDA profit, the company reported a net loss of ~£37m in FY2025 on an IFRS basis, reflecting depreciation, amortisation and financing costs.
- High leverage: Debt-to-equity ratio ~112%; new $100m debt facility plus £60m equity placement in 2025 addressed immediate needs but balance sheet remains stretched.
- Dilution history: Share count has grown from ~80m to ~121m over the last five years through equity raises. Further dilution is possible if growth capex requires additional funding.
- Client concentration: BMS (via Novartis-legacy CAR-T manufacturing) and a small number of major pharma clients represent a significant portion of revenue. Loss of a major client would be material.
- H1 2026 EBITDA-negative: Management has guided that H1 will be EBITDA-negative due to scheduled maintenance shutdowns, technology transfers and Durham facility integration, creating a lumpy earnings profile.
- Competitive intensity: Lonza, Thermo Fisher, Catalent/Novo Holdings, Fujifilm Diosynth and WuXi have greater scale and broader service offerings. Pricing pressure is possible as large CDMOs invest in viral vector capacity.
- Regulatory risk: Gene therapy manufacturing is highly regulated. Any GMP failure, product contamination or regulatory hold could damage client relationships and revenue.
- Clinical trial dependency: Revenue ultimately depends on clients’ clinical trial success. Program cancellations or clinical holds directly reduce manufacturing demand.
- Valuation: At ~£750m market cap on £170m revenue, the stock is priced for significant growth execution. Forward P/E is very high (~200x+ trailing) given losses; the business must grow into its valuation.
3. What Does Oxford Biomedica Actually Do?
Oxford Biomedica is a pure-play viral vector CDMO — it manufactures the delivery vehicles (viral vectors) that gene and cell therapy companies need to get their therapeutic genes into patient cells. The company specialises in two vector platforms: lentiviral vectors (used in CAR-T cell therapies like Novartis/BMS’s Kymriah) and adeno-associated viral (AAV) vectors (used in gene therapies for genetic diseases, eye conditions and neurological disorders).
Revenue by service type (FY2025, approximate):
| Service | Description | Pipeline mix |
|---|---|---|
| Process development | Developing and optimising the manufacturing process for a client’s specific vector product; includes cell line development, upstream/downstream process design | ~50% preclinical/Phase I |
| Clinical manufacturing (GMP) | Manufacturing viral vector batches to GMP standards for use in clinical trials (Phase I–III) | ~50% Phase II–III and commercial |
| Commercial manufacturing | Large-scale, ongoing GMP manufacturing for approved therapies (e.g., Kymriah lentiviral vectors for BMS) | 8 late-stage/commercial programs |
Vector type mix (Jan 2026 pipeline view): 43% AAV, 40% lentiviral, 17% other. This marks the first time AAV has exceeded lentiviral in OXB’s pipeline, reflecting the company’s successful expansion beyond its lentiviral heritage.
Geographic footprint. Oxford, UK (headquarters and primary manufacturing campus — multiple GMP suites); Durham, North Carolina, USA (FDA-approved commercial-scale facility acquired 2024/25, providing end-to-end US manufacturing). The dual UK/US footprint is strategically important given that the majority of gene therapy sponsors are US-domiciled.
4. The Business Model
How they make money. OXB earns revenue through a combination of:
- Service fees — Process development, technology transfer and GMP manufacturing under client contracts. Revenue is recognised as performance obligations are met.
- Batch-based manufacturing — Each GMP batch manufactured for a clinical trial or commercial product generates revenue. As programs progress to later stages and commercial launch, batch volumes and revenue per program increase.
- Licensing / royalties — OXB’s proprietary LentiVector® platform generates milestone and royalty income when client products using the platform achieve regulatory or commercial milestones.
Unit economics. FY2025 operating EBITDA margin was ~4.7% (£8.1m on £170.9m revenue) — the first positive year since the CDMO pivot. Management targets ≥20% EBITDA margin by 2027, driven by operating leverage (fixed-cost manufacturing suites generating higher utilisation), the shift toward higher-value commercial manufacturing, and Durham facility integration.
Moat. Oxford Biomedica’s competitive advantages include: (a) 30 years of lentiviral vector expertise originating from the University of Oxford, including the proprietary LentiVector® platform; (b) one of the largest dedicated lentiviral GMP manufacturing capacities globally; (c) expanding AAV capability; (d) dual UK/US manufacturing footprint with FDA-approved commercial facilities; (e) long-term relationships with tier-one pharma (BMS, and undisclosed major clients); (f) the new Fast-Track platform cutting development timelines by up to 50%.
Revenue visibility. Revenue backlog of £204m at end-2025 (+36%) and contracted client orders of £224m provide ~60% coverage of FY2026 guidance, rising to >80% including risk-adjusted pipeline. This is strong visibility for a CDMO business.
5. Financial Health
5-year trend (fiscal years ending 31 December; GBP millions).
| Year | Revenue | YoY % | Op EBITDA | IFRS net income | Cash & equivalents |
|---|---|---|---|---|---|
| 2021 | £128m | +53% | n/a (pre-CDMO pivot reporting) | £11m | ~£100m |
| 2022 | £113m | −12% | n/a | −£36m | ~£83m |
| 2023 | £89.5m | −21% | −£15m (est.) | −£62m | ~£45m |
| 2024 | £128.8m | +44% | −£4m (est.) | −£52m | ~£50m |
| 2025 | £170.9m | +33% | £8.1m | −£37m | ~£54m |
Note: 2021–2022 revenue included significant COVID-19 vaccine manufacturing revenue (AstraZeneca). The dip in 2022–2023 reflects the wind-down of vaccine contracts and transition to pure CDMO operations. The growth trajectory since 2023 represents organic CDMO business only.
Balance sheet. Cash of ~£54m at end-2025. Total debt includes a new $100m facility and existing obligations; debt-to-equity ratio ~112%. An equity placement of £60m in 2025 bolstered the balance sheet. Net debt (enterprise value minus market cap) implies ~£50m net debt. Capex guidance is ~£50m for 2026–27 to support Durham integration and Oxford site expansion. Analysts expect the company to turn net-profit positive in FY2026 (est. ~£12m).
6. Valuation & Market Data
Raw metrics, mid-April 2026. Not opinions on whether the stock is cheap or expensive.
| Metric | Value |
|---|---|
| Share price (LSE, 21 Apr 2026, approx.) | ~620–630p |
| 52-week range | ~270p – 950p |
| Market capitalisation | ~£750m |
| Enterprise value | ~£795m |
| Trailing P/E (GAAP) | n/m (net loss) |
| Forward P/E (FY2026e) | ~60–65x (on estimated £12m net profit) |
| P/S (trailing, on FY2025 revenue) | ~4.4x |
| EV/Revenue (trailing) | ~4.7x |
| EV/Revenue (FY2026e, at £230m midpoint) | ~3.5x |
| EV/EBITDA (FY2025) | ~98x (on £8.1m EBITDA) |
| EV/EBITDA (FY2026e, at ~10% margin) | ~34x |
| Dividend yield | Nil (no dividend) |
| Shares outstanding | ~120.9m |
| Analyst consensus target | ~882p (for reference only; not endorsed) |
7. What Are They Building / What’s Coming?
Fast-Track platform (April 2026). Launched 13 April 2026: an expedited development and manufacturing offering that cuts lentiviral vector development from the industry-standard 12–18 months to as little as 9 months, and offers similar acceleration for AAV vectors. This targets clients racing to IND filings and is a significant competitive differentiator.
Durham (NC) facility integration. The FDA-approved commercial-scale facility acquired in 2024/25 gives OXB an end-to-end US manufacturing footprint. Integration is ongoing through H1 2026 (contributing to H1 EBITDA drag). Once fully operational, Durham approximately doubles OXB’s commercial manufacturing capacity and reduces regulatory friction for US-domiciled clients.
AAV platform expansion. OXB has successfully expanded from its lentiviral heritage into AAV vectors, with AAV now representing 43% of the pipeline (vs 40% lentiviral). This is critical because AAV-based gene therapies (for genetic diseases, ophthalmology, neurology) represent a larger addressable market than lentiviral-based CAR-T.
BMS commercial supply agreement. New multi-year agreement announced February 2026 for lentiviral vector manufacture for BMS’s CAR-T programmes (including Kymriah legacy). Commercial manufacturing expected to start in 2026. This deepens OXB’s relationship with its largest historical client.
Pipeline progression. Late-stage plus commercial programs rose from 5 (2024) to 8 (March 2026). At least one program is expected to achieve commercial launch in 2026. Each commercial launch converts from project-based to recurring batch manufacturing revenue with higher margins.
Oxford campus expansion. Continued investment in GMP suite capacity and process development laboratories at the Oxford headquarters, funded from the ~£50m/year capex envelope.
Proprietary LentiVector® platform. OXB’s proprietary technology platform generates milestones and royalties when client products using the platform achieve regulatory approvals. This creates an option-value revenue stream that scales with the cell and gene therapy market.
8. Competitive Landscape
The viral vector CDMO market is moderately fragmented. Large diversified CDMOs compete with specialist players. OXB holds approximately 6% market share in a market growing at ~12% CAGR.
| Competitor | Ticker / exchange | Revenue (latest) | Stronghold | Key overlap with OXB |
|---|---|---|---|---|
| Lonza Group | LONN / SIX | ~CHF 7.5bn (group) | Biologics CDMO (mAb, ADC, viral vectors); largest scale | Viral vector manufacturing at all scales; established commercial manufacturing for approved gene therapies |
| Thermo Fisher (Patheon) | TMO / NYSE | ~$43bn (group) | End-to-end pharma services inc. viral vector manufacturing | Cell therapy / viral vector CDMO services as part of broader biologics and drug product offering |
| Catalent (Novo Holdings) | Private (acq. 2024) | ~$4bn (pre-acquisition) | Drug delivery, biologics, cell & gene therapy manufacturing | AAV and lentiviral vector manufacturing; large-scale commercial capacity |
| Fujifilm Diosynth | Subsidiary of 4901.T | N/A | Process development, viral vector, gene therapy manufacturing | Growing viral vector capacity; recently expanded US and European facilities |
| WuXi Advanced Therapies | 2269.HK / WuXi group | N/A | Cell & gene therapy CDMO; cost-competitive | Lentiviral and AAV vector manufacturing at scale; US + China dual footprint |
| Charles River Labs | CRL / NYSE | ~$4bn (group) | Discovery-to-commercial CRO/CDMO; acquired Vigene Biosciences | AAV viral vector services; upstream process development |
Competitive colour: OXB differentiates as a mid-tier specialist with 30 years of lentiviral expertise, proprietary LentiVector® technology and a strong European manufacturing base now complemented by US capacity. The large diversified CDMOs (Lonza, Thermo Fisher) offer broader service portfolios but less vector-specific depth. WuXi is cost-competitive but faces geopolitical headwinds (US BIOSECURE Act concerns). The Fast-Track platform launched in April 2026 is OXB’s latest move to differentiate on speed.
9. Leadership and Ownership
Dr Frank Mathias has been CEO since March 2023. He previously led Rentschler Biopharma SE as CEO, transforming it into a leading global full-service CDMO, and before that served as CEO of Medigene AG (listed immuno-oncology company). His appointment marked OXB’s definitive pivot to pure-play CDMO operations.
Key executives (April 2026):
- Dr Frank Mathias — Chief Executive Officer
- Stuart Paynter — Chief Financial Officer
- Lisa James — Chief People Officer
- John Foy — Site Head, Durham Operations (joined January 2026)
- Dr Frédéric Roch Doliveux — Chairman of the Board (since 2020)
Ownership. Institutionally held. Major shareholders include Novo Holdings (significant stake via various funds), Baillie Gifford, and other UK/European institutional investors. Free float is high. No single shareholder holds a controlling position.
Insider transactions. Director dealings have been limited to routine share plan vestings. CEO Frank Mathias holds shares acquired via the company share plan. No material discretionary insider purchases or sales have been disclosed in the last 90 days.
<\!-- TradingView Technical Analysis Gauge -->10. Risks and Challenges
- Profitability not yet proven at scale: FY2025 EBITDA of £8.1m is the first positive year. H1 2026 is guided EBITDA-negative. The path to ≥20% margins by 2027 requires flawless execution on Durham integration, client ramp-ups and operating leverage.
- Balance sheet leverage: Debt-to-equity ~112% is elevated for a company not yet consistently profitable on an IFRS basis. The $100m facility and £60m equity raise provide runway, but further fundraising cannot be ruled out.
- Dilution risk: Share count has grown from ~80m to ~121m over five years. Further equity issuance to fund growth capex or working capital is a possibility that would dilute existing shareholders.
- Client concentration: BMS and a small number of major pharma clients dominate revenue. Loss of a key client contract, clinical trial failure or strategic reprioritisation by a major client would materially impact revenue.
- Clinical trial dependency: OXB’s revenue depends on its clients’ clinical success. Program cancellations, FDA clinical holds or adverse trial results reduce manufacturing demand. OXB does not control this risk.
- Competitive intensity: Lonza, Thermo Fisher, Catalent and Fujifilm are investing heavily in viral vector capacity. Pricing pressure is possible as supply catches up with demand. WuXi offers cost-competitive alternatives.
- Regulatory / GMP risk: Any manufacturing failure, contamination event or regulatory citation at the Oxford or Durham facilities could halt production and damage client trust.
- Technology platform risk: Gene therapy is evolving rapidly. Non-viral delivery methods (lipid nanoparticles for gene editing) could eventually reduce demand for viral vectors, though this is a long-term risk.
- Currency exposure: Revenue increasingly includes USD-denominated contracts (Durham, US clients) while the cost base is partly GBP. GBP/USD movements affect reported results.
- Valuation priced for growth: At ~4.4x P/S and ~34x FY2026e EV/EBITDA, the stock is priced for continued high-growth execution. Any guidance miss would likely result in significant share-price downside.
11. Recent Developments
Last 48 hours (to 21 April 2026):
- 20 Apr 2026 — OXB shares gap up at market open on continued positive sentiment following the Fast-Track platform launch and BMS commercial supply agreement momentum.
Last 2 weeks:
- 13 Apr 2026 — Fast-Track viral vector development service launched. Cuts lentiviral development timelines from 12–18 months to as little as 9 months; similar acceleration for AAV. Targets clients racing to IND filings.
Last 6 months:
- 26 Mar 2026 — FY2025 preliminary results: revenue £170.9m (+33%), first full-year operating EBITDA profit of £8.1m. Backlog £204m (+36%). New FY2026 guidance: £220–240m revenue, ~10% EBITDA margin. Medium-term targets: 25–30% growth, ≥20% EBITDA margin by 2027.
- Feb 2026 — New multi-year Commercial Supply Agreement with BMS for lentiviral vector manufacture for CAR-T programmes. Commercial manufacturing to start in 2026.
- Jan 2026 — John Foy joined as Site Head, Durham Operations, strengthening US leadership.
- Jan 2026 — Pipeline update: AAV opportunities (43%) surpassed lentiviral (40%) for the first time. Late-stage + commercial programs at 8.
- Sep 2025 — H1 2025 interim results: revenue £78.4m (+29%); H1 on track for full-year guidance. Confirmed medium-term 35%+ revenue CAGR target (2023–2026).
12. Key Dates Coming Up
- 7 May 2026 — Annual General Meeting (Oxford).
- H1 2026 — BMS commercial manufacturing expected to begin under new supply agreement.
- Sep 2026 (est.) — H1 2026 interim results.
- 2026 — At least one client program expected to achieve commercial launch, triggering recurring commercial manufacturing revenue.
- Mar 2027 (est.) — FY2026 preliminary results.
- 2027 — Target year for ≥20% operating EBITDA margin.
Related pages: Live charts | Economic calendar | ChartsView forum | Blog
Disclaimer: This research is for information only and is not investment advice or a recommendation to buy or sell any security. All figures are sourced from Oxford Biomedica filings, RNS announcements, and public market data as at the date above. Forward-looking statements are attributed to the company and may not be achieved. Always do your own research.